Does Acalabrutinib Fit Into Frontline MCL Therapy?December 11, 2024Mantle Cell LymphomaB Cell LymphomaASH 2024
POLARIX: Extended Results Confirm Standard of Care for DLBCLDecember 11, 2024DLBCLNon-Hodgkin LymphomaASH 2024
Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune ThrombocytopeniaDecember 10, 2024Bleeding DisordersThrombosisASH 2024
Epcore NHL-1 Update: Treatment Effective Before CAR TDecember 10, 2024DLBCLB Cell LymphomaNon-Hodgkin LymphomaCellular TherapyASH 2024
High-Fiber Diet Linked to Improved Stem Cell Transplant, GvHD OutcomesDecember 9, 2024TransplantPatient & Survivor CareALLCLLNon-Hodgkin LymphomaMyelodysplastic SyndromeMixed Topics
24-Hour Urine Testing in Multiple Myeloma: Time to Stop?December 9, 2024Multiple MyelomaPatient & Survivor CareASH 2024
IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts SurvivalDecember 9, 2024Multiple MyelomaASH 2024
LBCL: Bispecific Antibodies Fare Less Well in Real-World AnalysisDecember 9, 2024DLBCLB Cell LymphomaNon-Hodgkin LymphomaPatient & Survivor CareASH 2024
ASH 2024: New Leukemia Txs, Fewer Blood Clots With GLP-1 RxsDecember 9, 2024ALLCLLBleeding DisordersThrombosis
New Cancer Vaccines on the Horizon: Renewed Hope or Hype?December 6, 2024Patient & Survivor CareMixed TopicsT Cell LymphomasIndolent LymphomaHodgkin LymphomaAggressive Lymphomas
Watch That Attitude: Is There Ageism in Healthcare?December 2, 2024Diversity in MedicineBusiness of Medicine
Inside the Patient-Oncologist Bond: Why It’s Often So StrongDecember 2, 2024Patient & Survivor CareMixed TopicsDLBCLMultiple MyelomaAMLAggressive LymphomasALL
